• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Evaluation of Different Doses in Inhaled Therapy: A Comprehensive Analysis.吸入疗法中不同剂量的评估:综合分析
Pharmaceutics. 2023 Aug 26;15(9):2206. doi: 10.3390/pharmaceutics15092206.
2
Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over.不同吸入性糖皮质激素及其与长效β2受体激动剂联合使用治疗12岁及以上成人和儿童慢性哮喘比较效果的系统评价与经济学分析
Health Technol Assess. 2008 May;12(19):iii-iv, 1-360. doi: 10.3310/hta12190.
3
Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.吸入装置在哮喘和慢性阻塞性气道疾病中的有效性比较:文献系统评价
Health Technol Assess. 2001;5(26):1-149. doi: 10.3310/hta5260.
4
Inhaled corticosteroids in children with persistent asthma: effects on growth.吸入性糖皮质激素对持续性哮喘儿童生长发育的影响
Evid Based Child Health. 2014 Dec;9(4):829-930. doi: 10.1002/ebch.1988.
5
Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in children under the age of 12 years.不同吸入性糖皮质激素及其与长效β2受体激动剂联合使用治疗12岁以下儿童慢性哮喘的比较效果的系统评价和经济学分析
Health Technol Assess. 2008 May;12(20):1-174, iii-iv. doi: 10.3310/hta12200.
6
Inhaled corticosteroids in children with persistent asthma: effects of different drugs and delivery devices on growth.持续性哮喘儿童吸入糖皮质激素:不同药物和给药装置对生长的影响。
Cochrane Database Syst Rev. 2019 Jun 10;6(6):CD010126. doi: 10.1002/14651858.CD010126.pub2.
7
Inhaled corticosteroids in children with persistent asthma: dose-response effects on growth.持续性哮喘儿童吸入糖皮质激素:对生长的剂量反应效应
Evid Based Child Health. 2014 Dec;9(4):931-1046. doi: 10.1002/ebch.1989.
8
An evaluation of early medication use for COPD: a population-based cohort study.慢性阻塞性肺疾病早期药物使用情况评估:一项基于人群的队列研究。
Int J Chron Obstruct Pulmon Dis. 2016 Dec 7;11:3101-3108. doi: 10.2147/COPD.S123643. eCollection 2016.
9
Incidence of oral thrush in patients with COPD prescribed inhaled corticosteroids: Effect of drug, dose, and device.慢性阻塞性肺疾病(COPD)患者使用吸入性糖皮质激素时口腔念珠菌病的发生率:药物、剂量和装置的影响
Respir Med. 2016 Nov;120:54-63. doi: 10.1016/j.rmed.2016.09.015. Epub 2016 Sep 22.
10
New Versus Old: The Impact of Changing Patterns of Inhaled Corticosteroid Prescribing and Dosing Regimens in Asthma Management.新与旧:哮喘管理中吸入皮质类固醇的给药方案和剂量方案变化模式的影响。
Adv Ther. 2022 May;39(5):1895-1914. doi: 10.1007/s12325-022-02092-7. Epub 2022 Mar 14.

引用本文的文献

1
A dual methodology employing ion-pair chromatography and built-in UV spectrophotometry for quantifying recently approved combination of mometasone and indacaterol in a novel combined metered dose inhaler: assessing the greenness, carbon footprint, blueness, and whiteness.一种采用离子对色谱法和内置紫外分光光度法的双重方法,用于定量新型联合计量吸入器中最近获批的莫米松和茚达特罗组合:评估绿色度、碳足迹、蓝色度和白度。
BMC Chem. 2024 Aug 3;18(1):143. doi: 10.1186/s13065-024-01242-y.

本文引用的文献

1
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary.慢性阻塞性肺疾病全球倡议2023年报告:GOLD执行摘要。
Arch Bronconeumol. 2023 Apr;59(4):232-248. doi: 10.1016/j.arbres.2023.02.009. Epub 2023 Mar 1.
2
Deposition and Clinical Impact of Inhaled Particles in the Lung.吸入颗粒在肺部的沉积和临床影响。
Arch Bronconeumol. 2023 Jun;59(6):377-382. doi: 10.1016/j.arbres.2023.01.016. Epub 2023 Feb 9.
3
Recombinant Alpha-1 Antitrypsin as Dry Powder for Pulmonary Administration: A Formulative Proof of Concept.重组α-1抗胰蛋白酶干粉吸入剂:一种制剂概念验证。
Pharmaceutics. 2022 Dec 8;14(12):2754. doi: 10.3390/pharmaceutics14122754.
4
Escalation and de-escalation of therapy in chronic obstructive pulmonary disease. Is the inhaler important?慢性阻塞性肺疾病治疗的升级与降级。吸入器重要吗?
Arch Bronconeumol. 2021 Sep;57(9):604-605. doi: 10.1016/j.arbr.2021.06.011. Epub 2021 Jul 4.
5
High Adherence, Microbiological Control and Reduced Exacerbations in Patients With Non-Cystic Fibrosis Bronchiectasis Treated With Nebulised Colistin. A Prospective Observational Study.雾化多黏菌素治疗非囊性纤维化支气管扩张症患者的高依从性、微生物学控制及加重次数减少。一项前瞻性观察性研究。
Arch Bronconeumol. 2022 Dec;58(12):834-836. doi: 10.1016/j.arbres.2022.03.023. Epub 2022 Apr 27.
6
Is it Time to Readjust the Doses of Inhaled Corticosteroids in COPD?是时候调整慢性阻塞性肺疾病(COPD)吸入性糖皮质激素的剂量了吗?
Arch Bronconeumol. 2022 Aug;58(8):593-594. doi: 10.1016/j.arbres.2022.01.014. Epub 2022 Feb 13.
7
Is Inhaler Technique Adequately Assessed and Reported in Clinical Trials of Asthma and Chronic Obstructive Pulmonary Disease Therapy? A Systematic Review and Suggested Best Practice Checklist.哮喘和慢性阻塞性肺疾病治疗的临床试验中,吸入器技术的评估和报告是否充分?系统评价和建议的最佳实践清单。
J Allergy Clin Immunol Pract. 2022 Jul;10(7):1813-1824.e1. doi: 10.1016/j.jaip.2022.03.013. Epub 2022 Mar 29.
8
Inhalation Devices and Climatic Change.吸入装置与气候变化
Arch Bronconeumol. 2022 Mar;58(3):287. doi: 10.1016/j.arbres.2021.07.002. Epub 2021 Jul 16.
9
Global Initiative for Asthma Strategy 2021. Executive Summary and Rationale for Key Changes.《2021年全球哮喘防治创议策略》。执行摘要及关键变化的理论依据。
Arch Bronconeumol. 2022 Jan;58(1):35-51. doi: 10.1016/j.arbres.2021.10.003. Epub 2021 Oct 28.
10
Optimization and Application of an Efficient and Stable Inhalation Exposure System for Rodents.优化和应用一种高效稳定的啮齿动物吸入暴露系统。
AAPS PharmSciTech. 2022 Jan 6;23(1):50. doi: 10.1208/s12249-021-02191-8.

吸入疗法中不同剂量的评估:综合分析

Evaluation of Different Doses in Inhaled Therapy: A Comprehensive Analysis.

作者信息

Lopez-Campos José Luis, Reinoso-Arija Rocio, Ferrer Galván Marta, Romero Falcón Auxiliadora, Alvarez-Gutiérrez Francisco J, Ortega-Ruiz Francisco, Quintana-Gallego Esther

机构信息

Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Instituto de Biomedicina de Sevilla, IBiS, Hospital Universitario Virgen del Rocío, CSIC, Universidad de Sevilla, 41013 Seville, Spain.

Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, 28029 Madrid, Spain.

出版信息

Pharmaceutics. 2023 Aug 26;15(9):2206. doi: 10.3390/pharmaceutics15092206.

DOI:10.3390/pharmaceutics15092206
PMID:37765175
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10535234/
Abstract

BACKGROUND

Currently, there is a considerable degree of confusion over the dosage of inhaled medications. Here, we carried out a review of all the doses used for the devices used in inhalation therapy.

METHODS

We first performed a systematic search of the different inhalation devices included on the July 2023 Spanish Ministry of Health Billing List. We then consulted the Spanish Agency for Medicines and Health Products to find the updated official label and to obtain the information on the exact composition.

RESULTS

We identified 90 unique products, of which 22 were long-acting bronchodilators (and combinations thereof) and 68 were products containing inhaled corticosteroids (ICS). Overall, 10 products with bronchodilators and 40 with ICS were marketed with the metered dose, while 11 with bronchodilators and 28 with ICS were marketed with the delivered dose. In addition, in some bronchodilators, the drug was referred to as a type of salt, whereas in others the information referred to the drug itself.

CONCLUSIONS

Our data show that for each inhaled drug there may be up to four different doses and that the marketed name may refer to any of these. Clinicians must be aware of these different dosages when prescribing inhaled medications.

摘要

背景

目前,吸入药物的剂量存在相当程度的混乱。在此,我们对吸入疗法中使用的设备所采用的所有剂量进行了综述。

方法

我们首先对2023年7月西班牙卫生部计费清单中包含的不同吸入设备进行了系统检索。然后,我们咨询了西班牙药品和健康产品管理局,以获取最新的官方标签并获得有关确切成分的信息。

结果

我们识别出90种独特的产品,其中22种是长效支气管扩张剂(及其组合),68种是含有吸入性糖皮质激素(ICS)的产品。总体而言,10种含支气管扩张剂的产品和40种含ICS的产品以定量剂量销售,而11种含支气管扩张剂的产品和28种含ICS的产品以递送剂量销售。此外,在一些支气管扩张剂中,药物被称为某种盐类,而在其他产品中,信息提及的是药物本身。

结论

我们的数据表明,每种吸入药物可能有多达四种不同的剂量,且市售名称可能指其中任何一种。临床医生在开具吸入药物处方时必须了解这些不同的剂量。